Overview

Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
Aim of this randomized, double-blind, placebo-controlled, cross-over study is to investigate cannabinoid-induced changes in neurophysiological parameters in a group of 40 patients with secondary or primary progressive Multiple Sclerosis (MS).
Phase:
Phase 3
Details
Lead Sponsor:
Almirall, S.A.
Treatments:
Nabiximols